<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526042</url>
  </required_header>
  <id_info>
    <org_study_id>NMM-1816,16/16-1</org_study_id>
    <nct_id>NCT03526042</nct_id>
  </id_info>
  <brief_title>Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis</brief_title>
  <official_title>Angiotensin-II Receptor Antibody Blockade With Losartan in Patients With Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies
      previously studied in human diseases such as preeclampsia, transplantation and scleroderma.
      They act by binding to the AT1 receptor and their effects can be blocked with the use of
      angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators
      will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media
      thickness progression in patients with lupus nephritis compared to patients treated with
      enalapril.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angiotensin-II type 1 receptor antibodies (AT1R-Ab) are agonist antibodies directed against
      the second loop of the AT1 receptor. These antibodies have been studied in human diseases
      such as preeclampsia, transplantation and scleroderma. A previous study from the
      investigators' group found an elevated prevalence of AT1R-Ab in patients with lupus
      nephritis. As these antibodies have been linked to atherosclerosis development this open
      randomized clinical trial was designed to evaluate the effect of AT1R-Ab blockade with
      losartan compared to the use of enalapril in the progression of carotid intima-media
      thickness (CIMT) in patients with active lupus nephritis.

      Biopsy-proven lupus nephritis patients who tested positive for AT1R-Ab will be performed a
      CIMT measurement by Doppler ultrasound at the time of the biopsy and then at 12-months follow
      up.

      The primary outcome will be the change in the CIMT in the course of 12 months in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open randomized clinical trial with parallel group comparing AT1R-ab blockade with losartan and enalapril as a control group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid intima-media thickness change after 12 months of the intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Change in carotid intima-media thickness from baseline thickness at study entry to 12 months of follow up measured by Doppler ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Response to immunosuppressive treatment at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial pressure</measure>
    <time_frame>12months</time_frame>
    <description>Arterial pressure control recorded by 24-hour ambulatory blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Angiotensin receptor blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)</description>
    <arm_group_label>Enalapril</arm_group_label>
    <other_name>Angiotensin Converting Enzyme Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent form for the study

          -  Biopsy-proven lupus nephritis with proteinuria &gt; 1.5g/g by 24 hour urine protein to
             creatinine ratio

          -  Need for immunosuppressive induction to remission therapy according to the treatment
             physician

          -  Systemic lupus erythematosus diagnosis based on at least 4 American College of
             Rheumatology criteria

          -  Age between 16 and 50 years

        Exclusion Criteria:

          -  Patient does not want to participate in the study

          -  Comorbid disease such as diabetes mellitus with macro/microangiopathy, previous
             diagnosis of hypertension &gt;5 years, scleroderma

          -  Comorbid findings in the histopathological analysis of the renal biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis E Morales-Buenrostro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis E Morales-Buenrostro, PhD</last_name>
    <phone>54870900</phone>
    <phone_ext>4142</phone_ext>
    <email>luis_buenrostro@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan M Mejia-Vilet, MD,MSc</last_name>
    <phone>54870900</phone>
    <phone_ext>4142</phone_ext>
    <email>jmmejia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M Mejia-Vilet, MD,MSc</last_name>
      <phone>54870900</phone>
      <phone_ext>4142</phone_ext>
      <email>jmmejia@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Luis E Morales-Buenrostro, PhD</last_name>
      <phone>54870900</phone>
      <phone_ext>4142</phone_ext>
      <email>luis_buenrostro@yahoo.com.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Luis Eduardo Morales Buenrostro</investigator_full_name>
    <investigator_title>Clinical Professor of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

